Krikor Manoukian, MD
Allergy & Immunology · Burbank, CANPI 1740519586
Payments from drug & device makers
Across 445 payments — averaging $30.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$4K
- GSK$2K
- AstraZeneca$1K
- Sanofi$907
- Regeneron Healthcare Solutions, Inc.$791
- Takeda Pharmaceuticals U.S.A., Inc.$682
- plus $4K from 27 others
What the payments were for
- Consulting fees$2,50019%
- Travel & lodging$6825%
- Food & beverage$10,19076%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 31 | $3,748 |
| GSK | 104 | $1,945 |
| AstraZeneca | 42 | $1,201 |
| Sanofi | 29 | $907 |
| Regeneron Healthcare Solutions, Inc. | 35 | $791 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $682 |
| Pfizer | 35 | $636 |
| Novartis | 20 | $601 |
| CSL Behring | 18 | $400 |
| Genentech USA, Inc. | 12 | $337 |
| Genentech, Inc. | 3 | $333 |
| Boehringer Ingelheim | 13 | $290 |
| Grifols USA, LLC | 9 | $242 |
| Incyte Corporation | 7 | $187 |
| Pharming Healthcare, Inc. | 6 | $162 |
| Amgen(2 entities) | 6 | $139 |
| Kaleo, Inc. | 6 | $120 |
| Phadia US Inc. | 5 | $101 |
| Biocryst US Sales Co., LLC | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 5 | $86 |
| LEO Pharma Inc. | 4 | $78 |
| Shire North American Group Inc | 3 | $65 |
| Ionis Pharmaceuticals, Inc. | 2 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Blueprint Medicines Corporation | 1 | $28 |
| Merck | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 2 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Medline Industries LP | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,442 in reported general payments places this provider in the 75th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 59 | $243,905 |
| NucalaMepolizumab | 17 | $124,041 |
| Dupixent PenDupilumab | 28 | $105,418 |
| Dupixent SyringeDupilumab | 24 | $88,170 |
| TezspireTezepelumab-Ekko | 11 | $43,323 |
| Spiriva RespimatTiotropium Bromide | 34 | $22,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $17,794 |
| DuleraMometasone/Formoterol | 18 | $8,928 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,139 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $7,029 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $4,475 |
| Epinephrine | 21 | $4,401 |
| Ventolin HfaAlbuterol Sulfate | 45 | $2,629 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,475 |
| Azelastine Hcl | 94 | $2,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $333 | $243,90559 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,945 | $149,97465 claims |
| AstraZenecaTezspire | $1,201 | $43,32311 claims |
| Boehringer IngelheimSpiriva Respimat | $290 | $22,74334 claims |
| MerckDulera | $24 | $8,92818 claims |
| Hikma Pharmaceuticals USAEpinephrine | $22 | $4,40121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Burbank
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
- James WolfeSan Jose$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.